Wire · opportunities
ESC: Cytokinetics delves deeper on 'huge' Myqorzo readout, fueling cardiomyopathy expansion bid
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
Cytokinetics' Myqorzo (aficamten) showed significant clinical benefits in a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy (nHCM), potentially paving the way for FDA approval and expansion beyond its previous use in obstructive HCM. The treatment improved patient-reported symptoms, exercise capacity, and cardiac stress markers with manageable safety risks.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Cardiac drugmakers have a new treatment proof point in nHCM, creating a fresh route to market and FDA approval you can attempt to access now. If you build therapies or services for rare cardiomyopathy patients, this success opens urgent opportunities to expand offerings.
◆ Coverage
1 source · 28 Aug 2026
◆ Related on Wire
◆ Topics